Hyperbaric oxygen may be effective for acute coronary syndrome

Clinical question
How effective is adjunctive hyperbaric oxygen therapy (HBOT) in acute coronary syndrome (ACS)?

Bottom line
There is some evidence that HBOT, following an episode of ACS, reduces the risk of death, reinfarction, significant dysrhythmias and major adverse coronary events, as well as limiting the peak levels of creatine phosphokinase and improving left ventricular ejection fraction. HBOT may also reduce the time required to achieve relief from cardiac ischaemic pain.

Caveat
The incidence of adverse effects was poorly assessed by the studies. The small number of studies, the modest numbers of patients, and the methodological and reporting inadequacies of the primary studies included in this review demand a cautious interpretation. At present, the routine adjunctive use of HBOT cannot be justified.

Context
ACS includes acute myocardial infarction and unstable angina, is common and may prove fatal. HBOT (breathing pure oxygen at high pressures in a specially designed chamber) will improve oxygen supply to the threatened heart and may reduce the volume of heart muscle that is damaged.

Cochrane Systematic Review

PEARLS No. 347, February 2012, written by Brian R McAvoy.

PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners – developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the New Zealand Guidelines Group. New Zealanders can access the Cochrane Library free via www.nzgg.org.nz

PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online at: www.nzdoctor.co.nz; www.nzgg.org.nz; www.cochraneprimarycare.org